L-DOPA: chemical modifications and biological evaluation.
D000818:Animals; D000978:Antiparkinson Agents; D001763:Blepharoptosis / Q000139:chemically induced / Q000188:drug therapy; D002389:Catatonia / Q000139:chemically induced / Q000188:drug therapy; D004195:Disease Models, Animal; D006801:Humans; D007035:Hypothermia / Q000139:chemically induced / Q000188:drug therapy; D007980:Levodopa / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D010095:Oxotremorine; D010300:Parkinson Disease / Q000188:drug therapy; D012110:Reserpine; D013329:Structure-Activity Relationship; D014202:Tremor / Q000139:chemically induced / Q000188:drug therapy
D000978:Antiparkinson Agents; D007980:Levodopa; D010095:Oxotremorine; D012110:Reserpine